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Abstract: Oxidative stress-induced neuroinflammation is the prominent feature of neurodegenerative
disorders, and is characterized by a gradual decline of structure and function of neurons. Many
biochemical events emerge thanks to the result of this neurodegeneration, and ultimately provoke
neuroinflammation, activation of microglia, and oxidative stress, leading to neuronal death.
This cascade not only explains the complexity of events taking place across different stages, but
also depicts the need for more effective therapeutic agents. The present study was designed to
investigate the neuroprotective effects of newly synthesized benzimidazole containing acetamide
derivatives, 3a (2-(4-methoxyanilino)-N-[1-(4-methylbenzene-1-sulfonyl)-1H-benzimidazol-2-yl]
acetamide) and 3b (2-(Dodecylamino)-N-[1-(4-methylbenzene-1-sulfonyl)-1H-benzimidazol-2-yl]
acetamide) against ethanol-induced neurodegeneration in the rat model. Both derivatives were
characterized spectroscopically by proton NMR (1 H-NMR) and carbon-13 NMR (13 C-NMR) and
evaluated for neuroprotective potential using different pharmacological approaches. In vivo
experiments demonstrated that ethanol triggered neurodegeneration characterized by impaired
antioxidant enzymes and elevated oxidative stress. Furthermore, ethanol administration induced
neuroinflammation, as demonstrated by elevated expression of tumor necrotic factor (TNF-α), nuclear
factor κB (NF-κB), cyclooxygenase-2 (COX2), and ionized calcium-binding adapter molecule-1 (Iba-1),
which was further validated by enzyme-linked immunosorbent assay (ELISA). Treatment with 3a and
3b ameliorated the ethanol-induced oxidative stress, neuroinflammation, and memory impairment.
The affinity of synthesized derivatives towards various receptors involved in neurodegeneration
was assessed through docking analysis. The versatile nature of benzimidazole nucleus and its
affinity toward several receptors suggested that it could be a multistep targeting neuroprotectant.
As repetitive clinical trials of neuroprotectants targeting a single step of the pathological process have
failed previously, our results suggested that a neuroprotective strategy of acting at different stages
may be more advantageous to intervene in the vicious cycles of neuroinflammation.
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1. Introduction
Neurodegeneration is the gradual decline of the structure and function of neurons. Inflammation
and oxidative stress are pivotal mediators in the development of these neurodegenerative diseases
such as Alzheimer’s disease (AD), Parkinson’s disease, and ischemic brain injury [1–3]. Many other
biochemical events such as loss of ionic gradient, the release of excitatory neurotransmitters, and the
formation of toxic radicals occur thanks to the result of these neurological disorders. The accretion of
these toxic mediators further triggers neurodegeneration and, ultimately, death [4]. The homeostatic
equilibrium maintained naturally between reactive oxygen species (ROS) and endogenous antioxidants
plays a vital role in continuing healthy tissue life. Elevated ROS production predisposes human health to
several disorders such as neurodegenerative and inflammatory disorders [5–7]. Activation of microglia
is another important hallmark in central nervous system (CNS) inflammation, which plays a principal
role in immune response in the brain [8]. Activated microglia adopt several morphological forms,
each with distinct physiological potential [9]. The up-regulation of inflammatory processes causes the
activation of several pro-inflammatory genes, triggering microglial activation and its translocation
to the site of injury [10–12]. Several studies reportedly demonstrated the role of hyperactivated
microglial in oxidative stress and neurodegeneration [13]. Further, it promotes the secretion of several
inflammatory markers such as cyclooxygenase-2 (COX2), tumor necrosis factor (TNF-α), nuclear
factor κB (NF-κB), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-10 (IL-10). Such events
ultimately trigger neuronal susceptibility and vulnerability to apoptosis [14].
Consistent studies demonstrated the pivotal role of neuroinflammation in ethanol-induced
neurodegeneration via several transduction pathways [15]. The exact underlying molecular
mechanisms of ethanol-induced neurodegeneration are generally unknown [16], however, several
detrimental attributes of ethanol are linked to neurotoxicity [17,18]. Moreover, ethanol is involved
in the activation of toll-like receptors (TLRs) and nucleotide-binding oligomerization domain-like
receptors, or NOD-like receptors (NLRs), in glial cells, triggering downstream signaling cascade and
activating pro-inflammatory cytokines release [19]. These suggested mechanisms make neuronal cells
prone to inflammation, and complicate the prognosis of neuropathological disorders [20,21].
Heterocyclic compounds have inspired many scientists to synthesize innovative molecules
and to evaluate their biological properties [22,23]. Among heterocyclic ring containing molecules,
benzimidazole is one of the most promising moieties [24]. Benzimidazole is becoming a substantial
nucleus in medicinal chemistry research because of its high affinity towards a variety of receptors
of interest [25,26]. In the current pharmaceutical market, many clinically useful drugs contain
benzimidazole nucleus [27]. A number of benzimidazole nucleus-based agents have been
proven to have good anti-inflammatory potential [28,29]. Likewise, many compounds containing
benzimidazole moiety have been synthesized and evaluated for the treatment of neurodegenerative
diseases [30]. The present study aims to evaluate the effects of benzimidazole acetamide derivatives
on neuroinflammation and oxidative stress, which could eventually account for cellular protection.
If so, the potential molecular and cellular mechanisms underlying these effects still require further
delineation. The results obtained will not only help us to understand the cascading mechanisms
leading to cell death, but also provide a clue of potential multiple targeting therapeutics.
2. Material and Methods
2.1. Chemicals
All the starting materials were purchased from Daejung (South Korea) and Alfa-Aesar (Germany).
Digital Gallenkamp (Sanyo) apparatus was used to record the melting points of final compounds
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and was uncorrected. Proton NMR (1 H-NMR) and carbon-13 (13 C-NMR) spectra were checked
using Bruker AM-300 in DMSO-d6 at 300 MHz and 75 MHz, respectively, while using TMS as
an internal standard. Alpha Bruker FTIR spectrophotometer (ATR eco ZnSe, νmax in cm−1 ) was
used to record FTIR spectra. All reactions were monitored by thin-layer chromatography (TLC).
3,3-diaminobenzidine peroxidase, an ABC Elite kit, mouse anti-COX-2, mouse anti-p-NF-κB, and
mouse anti-Iba-1 were procured from (Santa Cruz Biotechnology, Dallas, TX, USA). H2 O2 , Proteinase
K, formaldehyde, mounting media, and PBS tablets were acquired from BDH while secondary
antibody goat anti-mouse was purchased from Abcam (Cambridge, UK). Other chemicals were
procured from Sigma-Aldrich (St. Louis, MO, USA) like solvents and reagents such as 5,50 -dithiobis
(2-nitrobenzoic acid), 1-chloro-2,4-dinitrobenzene, glutathione (GSH), N-(1-naphthyl) ethylenediamine
dihydrochloride, and trichloroacetic acid. All chemicals used were of high analytical grade (99% HPLC).
2.2. General Procedure for the Synthesis of Benzimidazole Acetamide Derivatives (3a and 3b)
2-amino benzimidazole derivatives 3a and 3b were synthesized following a three-step
reaction. Initially, 2-aminobenzimidazole was protected using para toluene sulfonyl chloride
(p-TsCl) in the presence of an acetonitrile/water mixture according to a reported method with
little modification [31]. In the second step, acetamide was prepared using chloroacetyl chloride
(C2 H2 Cl2 O) in anhydrous dichloromethane, CH2 Cl2 (30 mL), at 0 ◦ C. Initially, the reaction
mixture was stirred continuously for 15 min on the same temperature, and then it was
stirred for further 1 h at ambient temperature/room temperature. Needle-like crystals of crude
2-chloro-N-[1-(4-methylbenzene-1-sulfonyl)-1H-benzimidazol-2-yl] acetamide were obtained, which
were further purified through recrystallization in ethanol. The melting point was recorded as
99–102 ◦ C; yield 82% [32]. In the third step, the equimolar ratios of the intermediate product,
triethylamine ((CH3 )3 N), potassium iodide (KI), and substituted amines (a and b), respectively, were
stirred in dimethylformamide (DMF) (30 mL) at room temperature for 5 h (Figure 1: general scheme).
The completion of the reaction was assessed by using TLC. The mixture was extracted with ethyl acetate.
Anhydrous magnesium sulfate was used to dry the separated organic layer, which was then filtered,
and the solvent was removed using a rotary evaporator to obtain the crude final compounds. The purity
of the respective final compounds was ensured through silica gel column chromatography [33].

Figure 1. General scheme to synthesize novel benzimidazole acetamide derivatives. DMF, dimethylformamide.

2.3. Molecular Docking
The molecular docking studies of synthesized compounds were performed to get an insight into
their binding preferences at the active site of the receptors using Autodock Vina software (San Diego,
CA, USA, version 4.2.6). The X-ray crystal structures of target proteins COX2 (PDB ID: 5IKQ), TNF-α
(PDB ID: 2AZ5), IL-1β (PDB ID: IT4Q), IL-6 (PDB ID: 2I3Y), IL-10 (PDB ID: 2H24), and Iba-1 (PDB
ID: 2G2B) were downloaded from http://www.rscb.org/pdb. Active sites of proteins were obtained
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from DoGSiteScorer, an active site prediction tool [34]. The protein–ligand complexes retrieved from
the protein data bank were prepared for docking. Co-crystallized ligands and water molecules were
removed from complex and saved as PDB files using Discovery Studio Visualizer. The structures of
the ligands were drawn in ChemSketch and saved as Mol files. PDB files of compounds and ligands
were generated using Open Babel software [35]. Moreover, proteins and ligands were converted to
PDBQT format using AutoDock Tools (version 1.5.6). Furthermore, docking of ligands into active sites
of proteins was carried out using Autodock Vina, a digital docking software that is used to interpret
results in the form of binding energies [36]. Discovery Studio Visualizer was used to analyze the best
binding poses and molecular interactions of ligands in each target protein. The docking procedure was
validated by the pose analysis of co-crystallized ligands with the re-docked conformations.
2.4. Animals and Drug Treatment
Adult male Sprague Dawley rats weighing between 250 and 290 g (age 10–12 weeks) were acquired
from the home-grown facility of Riphah Institute of Pharmaceutical Sciences, Riphah International
University (RIU). All the approved protocols were followed as set by the research and ethics committee
(REC), RIU. We divided the rats randomly and strictly followed the set criteria to allocate the same
weight animals to one group under similar experimental conditions. We divided rats into four groups
(12 animal/group) as follows: group I: saline group (control group) (1 mL/kg intraperitoneally for
eleven days), group II: ethanol group (2 g/kg intraperitoneally for 11 days), group III: ethanol +
compound 3a (ethanol injection (2 g/kg) followed by 3a injection (10 mg /kg) for 11 consecutive days),
and group IV: ethanol + compound 3b (ethanol injection (2 g/kg) followed by 3b injection (10 mg/kg)
for 11 consecutive days). At the end of the experiment, animals were killed according to the standard
protocol (diethyl ether inhalation method). Brain tissues (cortex and hippocampus) were collected and
thawed in PBS (pH 7.4 and approximately 5% w/v). For further analyses, the supernatant solution was
separated using a micropipette. To study the histology of tissues, brain tissue after collection were
stored in 5% paraformaldehyde, which was later implanted in paraffin, and 4 µm thin coronal sections
were made with a rotary microtome (five rats/group).
2.5. Behavioral Tests
2.5.1. Y-Maze Test
This test was performed in a special, Y-shaped apparatus. In this maze, each arm measures 50 cm
length, 20 cm height, and 10 cm width. Rats were assigned to five groups and each group consisted of
six animals. All these animals were injected with a single dose regimen per day for eleven consecutive
days. Group I was administered an intraperitoneal dose of saline solution (1 mL/kg) and designated as
control. Group II was designated as a disease group that received ethanol (2 g/kg). Animal group III
and group IV were assigned as treated groups, in which ethanol + 10 mg/kg dose of drugs 3a and 3b
was administered respectively, while Group V was given ethanol + standard drug donepezil (3 mg/kg).
A total of three sessions were performed, and each session lasted for 8 min. Briefly, each animal
was placed in the middle of the apparatus and permitted to move spontaneously through the maze.
A digital video recording camera was used to record all animal entries. The uninterrupted entry of the
animals into these three arms was defined as spontaneous alteration behavior. Meanwhile, the percent
(%) alteration behavior was defined as follows: successive triplet sets × entries into three different
arms successively/total number of arm entries − 2) × 100 [37]. The neurodegenerative potential was
assessed by an increase in spontaneous alternation behavior (%).
2.5.2. Morris Water Maze (MWM) Test
In the Morris water maze (MWM) test, all the groups and dosing were kept same as in the Y-maze
test. This test was piloted for three continuous days. One the first day, animals were trained for
swimming for 60 s in the absence of the probe. For the next two days, a probe was placed in the pool

Biomolecules 2020, 10, 108

5 of 16

and animals were trained to swim in the presence of this probe. As soon as the animal found that
probe, it was allowed to sit on it for 10 s. The rats that failed to locate the probe in 120 s were positioned
to stay on the probe for 10 s. After training, the animals were removed from the pool. Finally, on the
latter half of day 3, the individual rats were allowed to swim freely in the pool for 120 s in the absence
of the probe. Escape latency time was recorded for each animal [37]. The neurodegenerative potential
was calculated as a decrease in escape latency time.
2.6. Enzyme-Linked Immunosorbent Assays (ELISAs)
p-NF-κB, COX-2, and Iba-1 expression were measured using rat ELISA p-NF-κB (Cat # SU-B28069,
Shanghai Yuchun Biotechnology, Shanghai, China), rat COX-2 (Cat # E-EL-M0959, Elabscience
Biotechnology Inc., Houston, TX, USA), and rat Iba-1 (Cat # SU-B48003, Shanghai Yuchun Biotechnology,
Shanghai, China), respectively, according to the manufacturer’s instructions. Briefly, the supernatants
of brain tissue homogenates were collected and protein concentrations were treated with designated
antibodies in 96-well plates to quantify p-NF-κB, COX-2, and Iba-1. The concentration of p-NF-κB,
COX-2, and Iba-1 were determined using an ELISA microplate reader (BioTekELx808, Biotek, Winooski,
VT, USA) after the reaction between the enzyme and substrate. Values were expressed as pictograms
of cytokines per milliliter (pg/mL). All the procedures were repeated at least three times.
2.7. Morphological Analysis
For morphological analysis, brain samples were first embedded in paraffin blocks and subjected
to rotary microtome for trimming and 4 µm thin coronal tissue sections were made, and the following
morphological analysis was performed.
2.7.1. Hematoxylin and Eosin (H&E) Staining
Absolute xylene was used for the deparaffinization of the tissue slides and rehydration was done
using gradient ethyl alcohol (from 100% to 70%). Distilled water was used further to wash these slides
and they were dipped in hematoxylin for 10 min. Subsequently, slides were immersed in water and
then washed with 1% ammonia and 1% HCl water. Likewise, the eosin solution was used to treat these
slides for 5–10 min. Afterward, these slides were washed with water and dried in air. Dehydration of
these slides was done in a graded manner with ethyl alcohol (70%, 95% and 100%), and then they were
further washed with xylene, and glass coverslips were placed accordingly. Light microscopy (Olympus,
Tokyo, Japan) was used to take the images and ImageJ was used to analyze these images. Three
images were recorded per slide. All the images were strained to focus specifically on the inflammatory
infiltrated cells, neuron cell size, vacuolation, and neuron cell shapes. The same threshold intensity
was adjusted for all the TIF images.
2.7.2. Immunohistochemical Evaluation
Immunohistochemical staining was performed as in the reported method with a few
modifications [7]. After deparaffinization and graded hydration, antigens were retrieved by the
enzymatic method and then treated with PBS. Then, 3% H2 O2 in methanol was used for blocking
endogenous peroxidases for 10 min. Subsequently, incubation of these slides was done with normal
goat serum (5%) containing 0.1% Triton X-100, followed by overnight incubation with mouse antibodies
(anti-TNFα, anti-Iba-1, and anti-COX2) (dilution 1:100, Santa Cruz Biotechnology, USA). This process
continued for the next day. These slides were further incubated in biotinylated secondary antibody
(dilution 1:50) followed by washing with 0.1 M PBS solution. The incubation process continued,
next with the ABC Elite Kit in a humidified chamber for 1 h. Then, 0.1 M PBS was again used
for washing of slides, and staining was done with a solution of 3,3-diaminobenzidine peroxidase.
Further, slides were again washed in distilled water and graded ethanol dilutions were finally used
for dehydration. These slides were fixed in xylene and coverslips were placed properly using the
mounting medium. Light microscopy was used to take the immunohistochemical TIF images.
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2.8. Oxidative Enzymes Exploration
2.8.1. GSH and GSH S-Transferase (GST) Assay
Reported protocols were used to quantify the level of GSH. Previously diluted and homogenized
tissue was added with freshly prepared PBS and then with a solution of 5-50 -dithiobis (2-nitrobenzoic
acid). The 412 nm wavelength was used to check the absorbance of this solution. Similarly, the levels
of GSH S-transferase (GST) were assayed using reported protocol with little modifications. Concisely,
the same concentrations of GST and 1-chloro-2,4-dinitrobenzene were mixed and diluted with a 0.1 M
solution of PBS (pH 6.5). After serial dilution from tissue homogenate, the absorbance was measured
at 340 nm [6].
2.8.2. Lipid Peroxidation Assay
Lipid peroxide (LPO) assay was performed using a reported method with little modifications [38].
Lipid peroxide level was quantified by measuring the malondialdehyde (MDA) level in the cortical
and hippocampal brain tissues homogenate of rats.
2.8.3. Nitric Oxide Assay
Nitric oxide (NO) assay was performed according to the reported Griess reaction with little
modifications [39]. Briefly, 50 µl of previously diluted and homogenized tissue and 50 µl of normal
saline with an equal volume of Griess reagent (1% sulfanilamide in 0.1% naphthyl ethylenediamine
dihydrochloride and 5% phosphoric acid in distilled water) were mixed. The resultant mixture was
incubated for 30 min at 37 ◦ C and the absorbance was determined using a microplate reader at 546 nm,
with absorbance co-efficient calibrated using standard sodium nitrite solution.
2.9. Statistical Analysis
ImageJ was used to analyze the morphological data. Data are evaluated as mean ± SEM and
analyzed using the one-way analysis of variance (ANOVA) method followed by post hoc Bonferroni
multiple comparisons using Prism GraphPad-6 (San Diego, CA, USA). p < 0.05 was considered
statistically significant. Symbol # represents a significant difference relative to the saline group, and *
represents a significant difference relative to ethanol.
3. Results
3.1. Spectral Analysis of (3a) [2-(4-methoxyanilino)-N-[1-(4-methylbenzene-1-sulfonyl)-1H-benzimidazol-2-yl]
acetamide]
Yield, 89%; m.p., 168–170 ◦ C; Rf = 0.59 (ethyl acetate: n-hexane 1:5); FTIR νmax cm−1 : 3355(NH),
2957(sp2 CH), 2888 (sp3 CH), 1660 (CO amide), 1589 (C=C aromatic); 1 H-NMR: δ 2.32 (s, 3H, CH3),
3.34 (s, 2H, CH2), 3.65(s, 3H, OCH3), 4.09 (s, 1H, NH), 6.79 (d, 2H, Ar H, J = 9.0 Hz), 6.96 (d, 2H, Ar H,
J = 8.9 Hz), 7.31 (d, 2H, Ar H, J = 8.1 Hz), 7.52 (d, 2H, Ar H, J =8.1 Hz), 7.80 (d, 2H, Ar H, J = 8.4 Hz),
7.9 (d, 2H, Ar H, J = 5.7 Hz); 13 C-NMR (DMSO-d6, δ ppm); 22.1 (1C, sp3 C), 44.9 (1C, CH2), 55.5 (1C,
OCH3), 114.4–115 (4C, Ar), 117.5–125.5 (4C, Ar), 127–129.5 (4C, Ar), 135.5–142.3 (2C, Ar), 140.5 (2C,
Ar), 148.5–156.7 (2C, Ar), 154.7 (1C, sp3 C), 169.3 (1C, sp2 C).
3.2. Spectral Analysis of (3b) [2-(Dodecylamino)-N-[1-(4-methylbenzene-1-sulfonyl)-1H-benzimidazol-2-yl]
acetamide]
Yield, 83%; dark brown viscous liquid; Rf = 0.59 (ethyl acetate: n-hexane 1:5); FTIR νmax cm−1 :
3355(NH), 2959 (sp2 CH), 2890 (sp3 CH), 1665 (CO amide), 1580 (C=C aromatic); 1 H-NMR: δ 0.86 (s,
3H, CH3), 1.21–1.35 (m, 20H, 10*CH2, J = 7.0 Hz), 1.50 (t, 2H, CH2) 3.31 (s, 2H, CH2), 4.20 (s, 1H, NH),
7.80 (d, 2H, Ar H, J = 12.3 Hz), 7.98 (d, 2H, Ar H, J = 7.0 Hz), 7.29–7.41(m, 4H, Aromatic); 13 C-NMR
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(DMSO-d6, δ ppm); 14 (1C, CH2-N), 21.2 (1C, sp3 C). 22.6–30 (10C, CH2-N), 49.3 (1C, sp3 C), 57 (1C,
CO-CH2), 117–126 (4C, Ar), 127–144 (6C, Ar), 140.5 (2C, Ar), 152.7 (1C, sp2 C), 168 (1C, sp2 C).
3.3. Docking Evaluation
Synthesized compounds (3a and 3b) along with Co-crystallized ligands were docked into the
active sites of COX2, TNF-α, IL1-β, and Iba-1, and the results of docking study are summarized in
Table 1.
Table 1. Binding energy values after docking. IL, interleukin; TNF, tumor necrotic factor, COX,
cyclooxygenase; Iba, ionized calcium-binding adapter molecule.
Compounds

COX2

TNF-α

IL-1β

Iba-1

Binding Energies (kcal/mol)
3a
3b
Co-crystal

–8.9
–7.4
–9.1

–8.4
–7.4
–9.3

–7.6
–6
-

–7.3
–7
-

Re-docking of the co-crystallized molecules in the same protein was performed for the confirmation
and validation of the docking procedure. Figure 2A (A–D) show the poses and binding interactions
obtained for the re-docked and co-crystallized ligands in the protein structures of COX2 and TNF-α.
Pose analysis confirmed a near-perfect alignment with the original ligand and displayed the same
binding interactions as those obtained from the X-ray crystallographic PDB file. The binding mode and
interactions of compound 3a with COX2 are represented in Figure 2B (A–C). Compound 3a contains
a para toluene sulfonyl moiety in which the sulfonyl group was seen to form two hydrogen bonds
with Gln A:374, Arg A:376 residues, while para methyl and phenyl groups made hydrophobic contacts
with Leu145. The oxygen of the amide group was involved in hydrogen bonding with Asn B:376.
The attached para-methoxy phenyl substituent was stabilized by hydrophobic interaction with Leu
A:146. Figure 2B (D–F) depicted the binding pose of compound 3a with TNF-α. The para toluene
sulfonyl group was stabilized with pi–pi stacked interactions with Tyr A:119 and pi–alkyl contacts
with Tyr A:151 and Tyr A:59. Two hydrogen bonds were molded, one in between NH (amide) and Leu
B:120, and another between the amino group and Gly A:121. Hydrophobic interaction was observed
between the phenyl group of para-methoxy phenyl moiety and Tyr B:59.
The lowest energy binding poses and molecular interactions of compound 3a with IL1-β are
shown in Figure 2B (G–I). The NH group of amide, as well as amine, was stabilized through hydrogen
bonding with amino acid Val A:132 and Leu A:80, respectively. The benzimidazole scaffold and para
toluene sulfonyl moiety interacted with Thr A:79 and Phe A:123 by pi–sigma and pi–pi interactions.
Ligand–protein interactions of compound 3a with Iba-1 are illustrated in Figure 2B (J–L). Hydrogen
bonding was not observed in this case. Benzimidazole and phenyl ring fitted into the active site through
hydrophobic interactions with Tyr A:127, Leu A:73, Leu A:77, Ile A:124, and Met A:76. The best binding
pose and interactions of compound 3b with COX2 are represented in Figure 2C (A–C). The molecular
interactions of compound 3b with COX2 showed two hydrogen bonds, one between the sulfonyl
group and Gln A:372, and the second between the NH group and Ile A:124. Moreover, the complex
is stabilized by van der Waals force and hydrophobic interactions. Protein–ligand interactions of
compound 3b with TNF-α, IL-1β, and Iba-1 highlighted that only hydrophobic interactions were
observed in the stabilization of ligand in these targets (Figure 2C (D–L)).
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Figure 2.
(A) Pose analysis and 2D depictions for meclofenamic acid (A,B) and
6,7-dimethyl-3-[(methyl{2-[methyl({1-[3-(trifluoromethyl)phenyl]-1h-indol-3-yl} methyl)amino]ethyl}
amino)methyl]-4h-chromen-4-one (C,D) in the protein structures of cyclooxygenase-2 (COX-2) and
tumor necrotic factor (TNFα), respectively (green = co-crystallized ligand, red = re-docked ligand).
(B) Post docking analysis visualized by Discovery Studio Visualizer in both 2D and 3D poses. Interactions
between 3a and COX2 (A,B), TNF-α (D,E), interleukin (IL)-1β (G,H), and ionized calcium-binding
adapter molecule (Iba-1) (J,K). 3D poses (A,D,G,J) and 2D (B,E,H,K). (C,F,I,L) represents the best pose
of 3a that fitted to COX2, TNF-α, IL-1β, and Iba-1, respectively. (C) Post docking analysis visualized by
Discovery Studio Visualizer in both 2D and 3D styles. Interactions between 3b and COX2 (A,B), TNF-α
(D,E), IL-1β (G,H), Iba-1 (J,K). 3D style (A,D,G,J) and 2D style (B,E,H,K). (C,F,I,L) represents the best
pose of 3b that fitted to COX2, TNF-α, IL-1β, and Iba-1, respectively.

3.4. Effect of Compound 3a and 3b on Alternation Behavior
Both compounds 3a and 3b showed a positive increase in percent spontaneous alternation behavior
of rats through an injected dose of 10 mg/kg. In the final trial, the resultant behavior (%) was noted
in saline (1 ml/kg), ethanol (2 g/kg), ethanol + 3a (10 mg/kg), ethanol + 3b (10 mg/kg), and ethanol +
donepezil (3 mg/kg) treated groups as 47.0 ± 0.6%, 37 ± 0.65%, 57.40 ± 1.0%, 59 ± 2.1%, and 61.0 ± 1.2%,
respectively (Figure 3A). All group results were potentially significant (p < 0.05 vs. ethanol group).
3.5. Effect of Compound 3a and 3b on Escape Latency
The neuroprotective potential was studied by calculating the escape latency time for compounds
3a and 3b in the MWM test in three trials. Both derivatives produced significant results as compared
with the ethanol group. Escape latency time observed on day 1 in saline, ethanol, ethanol + 3a, ethanol
+ 3b, and ethanol + donepezil treated groups were 17.0 ± 1.2, 15 ± 1.1, 20.0 ± 0.5, 22 ± 0.5, and 26 ± 1.3,
respectively (Figure 3B). On day 2, it was noted as 16.0 ± 1.8, 12 ± 0.7, 21.0 ± 1.2, 23 ± 1.9, and 24 ± 1.4,
respectively, while in the final trial, it was noted as 14.0 ± 0.6, 11 ± 0.5, 22.0 ± 1.0, 25 ± 2.1, and 24 ± 1.2,
respectively. All group results were potentially significant (p < 0.05 vs. ethanol group).
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Figure 3. (A) Spontaneous alteration behavior % of the rats during the Y-maze test. Mean ± SEM
for the rats (n = 6/group). ## shows significantly different from the control; *, ** shows significantly
different from the ethanol-treated group. Significance: p < 0.05. (B) Average escape latency time for
experimental rats to reach the hidden platform from one to three days. Mean ± SEM for the rats
(n = 6/group). #, ## shows significantly different from the control; *, **, *** shows significantly different
from the ethanol-treated group. Significance: p < 0.05.

3.6. Effect on Ethanol-Induced Neurodegeneration
Neuroprotective potential of benzimidazole acetamide derivatives 3a and 3b was further
demonstrated by H&E staining. The ethanol group showed vigorous morphological changes in
the cortex and hippocampus of the rat brain, relative to the saline group (Figure 4, p < 0.01). As shown,
ethanol produced abnormal morphological features, such as scalloped neuronal shape associated with
cytoplasmic eosinophilia/pyknosis and basophilic nature of nuclei. Treatment with compounds 3a and
3b mitigated the ethanol-induced neurotoxicity, and thus more intact cells were noticed in the treated
groups (p < 0.05, Figure 4).
3.7. Pre-Treatment Dosage Regimen Downregulated Neuroinflammation
Resident microglia and astrocyte cells critically regulate the inflammation process, as these cells
are involved in mediating both detrimental effects by releasing cytokines and protective effects
due to brain-derived neurotrophic factor (BDNF) release [40]. The classical sign of microglia
activation (Iba-1 reactive cells) is its characteristic hypertrophic appearance, which we revealed
by immunohistochemistry. A significant increase in expression of Iba-1 reactive cells was noticed
in the ethanol-administered cortex and hippocampus relative to the saline cortex and hippocampus
(Figure 5A, p < 0.001), which was further validated by ELISA protein assay (Figure 5B, p < 0.05). These
effects were significantly reversed by pre-treatment with benzimidazole acetamide derivatives (3a and
3b) dosage regimen (Figure 5, p < 0.05).
The expression levels of TNF-α (an inflammatory cytokine) were also increased in the
ethanol brain, which supports glial cell involvement [41]. Both effects were reversed by
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pre-treatment with benzimidazole acetamide derivatives (3a and 3b) dosage regimen, as validated by
immunohistochemistry findings for TNF-α (Figure 5C, p < 0.05).

Figure 4. Representative immunohistochemical images of hematoxylin and eosin (H&E) and the
quantified histogram of the survival neuron reactivity and integrated density in the cortex and
hippocampus region of the adult cortex. The expressed data are relative to the control. ### shows
significantly different from the control; ∗ shows significantly different from the ethanol-treated group.
Significance: p < 0.05. Bar 20 µm, magnification 40× (n = 6/group).

Figure 5. (A) Immunohistochemistry results for Iba-1 in the cortex and Dg region of the hippocampus.
Bar 20 µm, magnification 40× (n = 6/group). Histograms show a comparatively higher expression of
Iba-1 in the ethanol group. ** and * show p < 0.01 and p < 0.05, respectively, and indicate significant
difference relative to ethanol, while ### p < 0.001 shows significant difference relative to saline group.
Data are presented as mean ± SEM. Data are analyzed by one-way analysis of variance (ANOVA)
followed by post hoc Bonferroni multiple comparison test using GraphPad Prism 6 software. (B) The
protein expression of Iba-1 quantified using enzyme-linked immunosorbent assays (ELISA). The data
were expressed as the mean ± SEM. * p < 0.05 relative to ethanol, while # p < 0.05 and ## p < 0.01 relative
to saline (n = 6/group). (C) Immunohistochemistry results of TNF-α in the cortex and Dg region of
the hippocampus. Bar 20 µm, magnification 40× (n = 6/group). Histograms show a comparatively
higher expression of TNF-α in the ethanol group. * shows p < 0.05 and indicates significant difference
relative to ethanol, while ### p < 0.001 shows significant difference relative to the saline group. Data are
presented as mean ± SEM. Data are analyzed by one-way ANOVA followed by post hoc Bonferroni
multiple comparison test using GraphPad Prism 6 software.
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3.8. Pre-Treatment Dosage Regimen Attenuated the Ethanol-Induced Inflammatory Mediators
The binding of pro-inflammatory factors TNF-α to respective receptors triggers sequential
activation of downstream molecules such as apoptosis signal-regulating kinase 1 (ASK1),
stress-activated protein/extracellular signal-regulated kinase 1 (SEK1), and c-Jun N-terminal kinase
(JNK). Collectively, this leads to proteasomal dependent IκB dissociation, and nuclear translocation
of NF-κB to induce inflammatory transcription machinery like COX2 [3]. These proteins were hyper
expressed in ELISA results in the ethanol brain (Figure 6A,B, p < 0.01). Benzimidazole acetamide
derivatives (3a and 3b) pre-treatment dosage regimen significantly alleviated this level (p < 0.05).
Immunostaining was performed to validate these findings. Similarly, the expression of COX2 was
noticed as being significantly high in ethanol-administered brain tissues, while treatment with 3a and
3b reduced this level (Figure 6C, p < 0.05).

Figure 6. (A,B) The protein expression of COX2 and p-NF-κB were quantified by ELISA. The data are
expressed as the mean ± SEM. * and ** show p < 0.05 and p < 0.01, respectively, relative to ethanol,
while ## p < 0.01 relative to saline (n = 6/group). (C) Immunohistochemistry results of COX2 in the
cortex and Dg region of the hippocampus. Bar 20 µm, magnification 40× (n = 6/group). COX2 exhibited
cytoplasmic localization in both tissues. Histograms show a comparatively higher expression of COX2
in the ethanol group. * shows p < 0.05 and indicates significant difference relative to ethanol, while ###
p < 0.001 shows significant difference relative to saline group. Data are presented as mean ± SEM. Data
are analyzed by one-way ANOVA followed by post hoc Bonferroni multiple comparison test using
GraphPad Prism 6 software.

3.9. Effect on Oxidative Enzyme Variations
Table 2 reveals the variation of antioxidant enzymes following ethanol, compound 3a, and
compound 3b treatment. Ethanol accumulated the ROS generation in addition to NO (85 ± 6 µg/mL)
and alleviated antioxidant enzymes levels such as GSH (3.30 ± 0.97) and GST (2.78 ± 0.45) in the brain
cortical tissue (p < 0.001). Treatment with 3a and 3b at a dose of 10 mg/kg attenuated downregulation
of GSH (34.3 ± 2.4) (40.7 ± 4.1) and GST (28.05 ± 4.3) (35.8 ± 5.1), along with a decreased level of NO
(63.15 ± 3.8) (65.2 ± 4.56), respectively, when compared with the ethanol group.
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Table 2. Effect of 3a and 3b on oxidative enzymes.
Group

GSH (mg/1100 g Tissue)

GST (pmol)

i-NOS (pmol)

LPO

Saline
Ethanol
Ethanol + 3a
Ethanol + 3b

54.88 ± 3.78
3.30 ± 0.97 ###
34.3 ± 2.4 **
40.7 ± 4.1 **

40.42 ± 1.30
2.78 ± 0.45 ###
28.05 ± 4.3 **
35.8 ± 5.1 ***

21.02± 7.61
85 ± 6 ###
63.15 ± 3.8 *
65.2 ± 4.56 *

79.32 ±0.70
224.54 ± 4.32 ###
160.45 ± 8.9 *
130.8 ± 2.82 **

Symbols *** or ### show significant difference at p < 0.001, while * and ** show significant difference at p < 0.05 and
p < 0.01, respectively. All data were analyzed by one-way analysis of variance (ANOVA) followed by post hoc
Bonferroni multiple comparison test. Data are presented as mean ± SEM. Symbol * shows a significant difference
relative to ethanol and # shows significant difference relative to saline. Abbreviations: GST, glutathione S-transferase;
GSH, glutathione; TBARS, thiobarbituric acid reactive substances; i-NOS, inducible nitric oxide synthase; LPO,
lipid peroxidation.

3.10. Effect on Ethanol-Induced Lipid Peroxidation (LPO)
Several reports declared malondialdehyde (MDA) as an important indicator to quantify oxidative
stress. Thiobarbituric acid reactive substances (TBARS) is a widely used method to assess lipid
peroxidation end product malondialdehyde (MDA). This test was performed accordingly, and the
results showed a valuable increase in peroxidases after ethanol administration, which could be treated
by compounds 3a and 3b. The increased LPO content in the ethanol-treated group was recorded as
(224.54 ± 4.32) in comparison with the saline group (p < 0.001, Table 2). Benzimidazole acetamide
derivatives (3a and 3b) at a dose of 10 mg/kg significantly (Table 2) reduced this content to (160.45 ± 8.9,
p < 0.05) and (130.8 ± 2.82, p < 0.01), respectively.
4. Discussion
During the last two decades, a variety of inflammatory mediators have been identified in
neurodegenerative brains [42], which might play a pathogenic role in the cortex and hippocampus [43].
The cortex and hippocampus, being more susceptible parts of the brain, are more affected during
the early stages of neurodegenerative diseases [44]. One of the important and successful strategies
to reduce microglial activation is the use of anti-inflammatory agents, such as drugs that inhibit
COX2, which reduces the neuroinflammation and improves behavioral deficits [45]. Furthermore, this
strategy protects against neurodegeneration in the hippocampus of an ethanol-exposed rat brain [46].
As the benzimidazole nucleus has a strong affinity towards multiple targets, toxicological studies have
proven it as a safer moiety for future drug design and development [47]. In the last few decades,
the benzimidazole nucleus has been reported in many pharmaceutical patents owing to its high
pharmacological value [48]. Similarly, many compounds containing benzimidazole nucleus have been
reported as potential anti-inflammatory agents [49,50]. Therefore, in our study, we established the
synthesis of two novel anti-inflammatory substituted benzimidazole compounds, which effectively
improved the neuroprotective effects through boosted antioxidant effect, as well as reduced oxidative
stress and neuroinflammation. Many established reports demonstrated that the benzimidazole
nucleus-containing drugs are highly suitable to produce beneficial effects against neuronal death in
many neurodegenerative disease models [51–53]. Reportedly, benzimidazole derivatives act not only
as an endogenous potent anti-oxidant and free radical scavenger in various pathological and disease
conditions [54,55], but also as an activator of many antioxidant systems. In particular, they activate
superoxide dismutase (SODs), GSH, Sirtuins (SIRTs), and nuclear factor erythroid 2-related factor
2/heme oxygenase-1 (Nrf2/HO-1) pathway. Many published reports evidently show a relationship
between the activation of inflammatory cascades and the accretion of oxidative stress [56,57].
These new compounds were synthesized by using the general scheme, shown in Figure 1,
with little modifications. The 2-aminobenzimidazole was converted to 1-[dihydroxy(4-methyl
phenyl)-λ4-sulfanyl]-1H-benzimidazol-2-amine by using para toluene sulfonyl chloride in
the presence of acetonitrile and water.
Further, it was reacted with CH2 Cl2 in
the presence of triethylamine and dried solvent (methylene chloride) to convert it into
2-chloro-N-[1-(4-methylbenzene-1-sulfonyl)-1H-benzimidazol-2-yl] acetamide. FTIR results confirmed
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the formation of intermediate compounds through the generation of new bonds such as amide bond
stretch at 1660 cm−1 (–CO) and stretching of (–NH) at 3355 cm−1 . The resultant derivatives (3a and
3b) were prepared by the nucleophilic reaction of the intermediate compound and primary amines
(p-anasidine and dodecylamine), respectively. One singlet of amide proton at δ = 4.09 confirmed
the formation of the amide bond in the intermediate product. Final confirmation of the resultant
derivatives was confirmed by FTIR, 1 H-NMR, and 13 C-NMR spectral results.
Neuroinflammation is directly linked with ROS provoked oxidative stress, which further
aggravates neurodegenerative disease pathogenesis. Neuroinflammation promotes the activation
of several inflammatory cytokines and mediators (COX2), inducible nitric oxide synthase (iNOS),
IL-6, IL-10, TNF-α, mitogen-activated protein kinases (MAPKs), nuclear factor-κB (NF-κB) activation,
and microglial activation (Iba-1) [58,59]. Treatment using our newly synthesized compounds produced
a profound neuroprotective effect by strengthening the intrinsic antioxidant effect (GSH, GST) and
also by attenuating proinflammatory cytokines and ROS generation. In different reported scenarios,
increased ROS production owing to oxidative stress and activated microglia presents an increased
risk of many morphological changes and neurodegeneration in the brain. In different repetitive trials,
many neuroprotective agents targeting neuroinflammation failed as a result of increased side effects,
lesser central nervous system (CNS) permeability, and reduced therapeutic activity because of usually
targeting a single site [60]. Our results demonstrated that a neuroprotectant with less hydrogen bond
donors and lesser polar surface area has a rapid CNS penetration and can act on multiple targets to
attenuate the oxidative stress-induced neuroinflammation. We hypothesize that our newly synthesized
derivatives can reduce neuronal injury by modulating cytokines’ expression and by downregulating
the p-NF-κB pathway.
5. Conclusions
In conclusion, ethanol injury activates several proinflammatory mediators including NF-κB and is
further linked to ROS generation. Our newly synthesized compounds attenuated ethanol-induced
oxidative stress and inflammatory cascade, possibly by modulating the ROS/TNF-α/NF-κB/COX2
pathway, eventually accounting for its neuroprotective effects against neuronal apoptosis.
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